TY - JOUR
T1 - Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis
T2 - A clinical evaluation
AU - Grutters, Jan C.
AU - Fellrath, Jean Marc
AU - Mulder, Leontine
AU - Janssen, Rob
AU - Van Den Bosch, Jules M.M.
AU - Van Velzen-Blad, Heleen
N1 - Funding Information:
Dr. Fellrath is supported by a grant from the Foundation SICPA, Lausanne, Switzerland.
PY - 2003/7/1
Y1 - 2003/7/1
N2 - Objectives: To date, insufficient evidence is available to recommend serum soluble interleukin-2 receptor (sIL-2R) measurement as a routine test in the assessment of sarcoidosis. Therefore, we evaluated the clinical value of this test. Design: Forty-seven patients with sarcoidosis, all presenting with active disease, were included in the study. Initial serum sIL-2R levels were determined by enzyme-linked immunosorbent assay, and clinical data at presentation and follow-up were collected retrospectively. Results: The median follow-up period of all patients was 44 months (range, 6 to 100 months), and 38 patients had follow-up data present over at least 24 months. The median sIL-2R level was 1,068 U/mL (range, 248 to 4,410 U/mL; upper limit of normal, 710 U/mL). A positive correlation was found between serum sIL-2R levels and the number of CD4+ T lymphocytes in BAL (rs = 0.53, p < 0.001). In accordance with this result, both sIL-2R level and the number of CD4+ T lymphocytes were elevated in stage I compared to stage III disease (p < 0.05). Patients with extrapulmonary disease (ED) [excluding Löfgren's syndrome] showed higher sIL-2R levels than those presenting with only pulmonary sarcoidosis (p = 0.001). No relation was found between sIL-2R level and response to treatment, and there was no association between sIL-2R levels and radiographic evolution and lung function outcome. Conclusions: Our data suggest a role for serum sIL-2R as marker of pulmonary disease activity and ED in patients with sarcoidosis.
AB - Objectives: To date, insufficient evidence is available to recommend serum soluble interleukin-2 receptor (sIL-2R) measurement as a routine test in the assessment of sarcoidosis. Therefore, we evaluated the clinical value of this test. Design: Forty-seven patients with sarcoidosis, all presenting with active disease, were included in the study. Initial serum sIL-2R levels were determined by enzyme-linked immunosorbent assay, and clinical data at presentation and follow-up were collected retrospectively. Results: The median follow-up period of all patients was 44 months (range, 6 to 100 months), and 38 patients had follow-up data present over at least 24 months. The median sIL-2R level was 1,068 U/mL (range, 248 to 4,410 U/mL; upper limit of normal, 710 U/mL). A positive correlation was found between serum sIL-2R levels and the number of CD4+ T lymphocytes in BAL (rs = 0.53, p < 0.001). In accordance with this result, both sIL-2R level and the number of CD4+ T lymphocytes were elevated in stage I compared to stage III disease (p < 0.05). Patients with extrapulmonary disease (ED) [excluding Löfgren's syndrome] showed higher sIL-2R levels than those presenting with only pulmonary sarcoidosis (p = 0.001). No relation was found between sIL-2R level and response to treatment, and there was no association between sIL-2R levels and radiographic evolution and lung function outcome. Conclusions: Our data suggest a role for serum sIL-2R as marker of pulmonary disease activity and ED in patients with sarcoidosis.
KW - Alveolitis
KW - Extrapulmonary disease
KW - Sarcoidosis
KW - Serum soluble interleukin-2 receptor
UR - http://www.scopus.com/inward/record.url?scp=0038159918&partnerID=8YFLogxK
U2 - 10.1378/chest.124.1.186
DO - 10.1378/chest.124.1.186
M3 - Article
C2 - 12853522
AN - SCOPUS:0038159918
SN - 0012-3692
VL - 124
SP - 186
EP - 195
JO - Chest
JF - Chest
IS - 1
ER -